BL-M07D1 plus pembrolizumab for advanced HER2‑overexpressing non-squamous NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open-label Phase II trial testing the safety and anti-tumor activity of the investigational agent BL‑M07D1 given together with pembrolizumab in patients with unresectable locally advanced or metastatic HER2‑overexpressing non‑squamous NSCLC. Eligible participants must have confirmed HER2 overexpression, at least one measurable lesion per RECIST v1.1, ECOG 0–1, adequate organ function, and recoveries from prior treatment toxicities. Archived tumor tissue is required for biomarker confirmation, and cardiac function must be acceptable (LVEF ≥50%). The trial will monitor tumor responses and adverse events to characterize tolerability and preliminary efficacy of the combination.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily sign the informed consent form and comply with the protocol requirements;
2. No gender restrictions;
3. Age at the time of signing the informed consent form ≥18 years and ≤75 years;
4. Expected survival time ≥3 months;
5. Patients with locally advanced or metastatic non-squamous non-small cell lung cancer;
6. Confirmed known HER2 overexpression;
7. Agree to provide archived tumor tissue specimens from primary or metastatic lesions within the past 2 years;
8. Must have at least one measurable lesion meeting the RECIST v1.1 criteria;
9. ECOG performance status score of 0 or 1;
10. Toxicities from prior anti-tumor treatments have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
11. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
12. Organ function levels must meet the requirements;
13. For premenopausal women with childbearing potential, a pregnancy test must be conducted within 7 days before starting treatment, serum pregnancy must be negative, and they must not be breastfeeding; all enrolled patients (regardless of gender) should take adequate and highly effective contraception throughout the treatment cycle and for 7 months after the end of treatment.

Exclusion Criteria:

1. Underwent surgical treatment, radical radiotherapy, immunotherapy, etc., within 4 weeks before the first dose or within 5 half-lives;
2. Pathology indicates non-small cell carcinoma containing small cell carcinoma components and sarcomatoid carcinoma;
3. Previously received HER2-targeted therapy or ADC drug treatment with camptothecin derivatives as toxins;
4. History of severe cardiovascular or cerebrovascular diseases within the past 6 months before screening;
5. Concurrent pulmonary disease leading to severe impairment of lung function;
6. QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
7. Diagnosed with other primary malignancies within 5 years before the first dose;
8. Poorly controlled hypertension;
9. History of non-infectious ILD requiring steroid treatment, or currently suffering from ILD/interstitial pneumonia, etc.;
10. Patients with central nervous system metastases, carcinomatous meningitis, and/or spinal cord compression;
11. Patients with a history of allergy to recombinant humanized antibodies or allergy to BL-M07D1, pembrolizumab, or any excipient components;
12. Required systemic corticosteroid or immunosuppressive therapy within 2 weeks before the study administration;
13. Patients with massive serous cavity effusion, symptomatic serous cavity effusion, or poorly controlled serous cavity effusion;
14. New deep vein thrombosis within 14 days, excluding patients with venous filters implanted;
15. Systemic severe infection within 4 weeks before screening;
16. Active autoimmune diseases and inflammatory diseases;
17. Human immunodeficiency virus antibody positivity, active hepatitis B virus infection, or hepatitis C virus infection;
18. History of allogeneic stem cell, bone marrow, or organ transplantation;
19. Presence of severe neurological or psychiatric disorders;
20. Presence of other severe physical or laboratory abnormalities, poor compliance, etc., which may increase the risk of participation in the study, interfere with study results, or patients deemed unsuitable for participation in the study by the investigator.

Where it's running

• Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Sa Xiao, PHD
• Email: xiaosa@baili-pharm.com
• Phone: 15013238943

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Aglatimagene Besadenovec with Prodrug and Pembrolizumab vs Docetaxel for Advanced Non-Squamous NSCLC

  This phase 3 trial tests whether giving aglatimagene besadenovec with a prodrug and pembrolizumab works better than standard chemotherapy (docetaxel) for adults with stage IV non-squamous NSCLC that progressed on pembrolizumab.

  Recruiting Phase 3 Candel Therapeutics, Inc. · New York, New York · NCT07660094

• Comparing Rilvegostomig and Pembrolizumab with Chemotherapy for Lung Cancer

  This study is testing whether a new drug called rilvegostomig or pembrolizumab, both used with chemotherapy, can help people with advanced lung cancer whose tumors have a specific marker.

  Recruiting at 246 sites Phase 3 AstraZeneca · Mobile, Alabama and 300 other locations · NCT06627647

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.